← Leaderboards
Ellen Mary Lavoie Smith
University Of Alabama At Birmingham
$2,422,741
Attributed
$3,233,098
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $776.3K · FY2015–25$1M$750K$500K$250K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,233,098 · 3
By mechanism
R01$1,751,508 · 1
T32$1,326,527 · 1
R03$155,063 · 1
Top collaborators
- Ritu Aneja3 shared
- Lyse A Norian2 shared
Most similar at University Of Alabama At Birmingham
Same institution · by research overlap
- Jianguo Gu$14,706,393
- Hsiao-Lan Wang$2,911,248
- Bradley K. Yoder$32,312,462
- Courtney Marie Peterson$4,655,471
- Robert B. Diasio$27,640,960
Others in their field
Top investigators on “National Cancer Institute”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,005,298,928
- Leonard Freedman · Leidos Biomedical Research, Inc.$839,578,040
- Larry Arthur$348,801,637
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$309,633,255
- Lynn Briscoe · Leidos Biomedical Research, Inc.$268,102,518
- Norman Wolmark · Nsabp Foundation, Inc.$249,775,372
Research focus
National Cancer InstituteDistressUnited StatesToxic EffectResearch DesignCommon Terminology Criteria For Adverse EventsPreventNumbnessQuality Of LifeSymptomsDoseCancer SurvivorQuestionnairesDesignChemotherapyChemotherapy-Induced Peripheral NeuropathyMalignant NeoplasmsFunctional DisabilityBaseDiagnosisAcademyCommunity Clinical Oncology ProgramFallsClinical Trials
Grant awards (12)
Cancer Prevention and Control Training Program$475,267
T32 · FY2025 · CA
Cancer Prevention and Control Training Program$407,297
T32 · FY2024 · CA
Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study$95,851
R01 · FY2024 · CA · contact PI
Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study$291,932
R01 · FY2023 · CA · contact PI
UAB Cancer Prevention and Control Training Program (T32)$443,963
T32 · FY2022 · CA
Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study$332,337
R01 · FY2022 · CA · contact PI
Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study$386,575
R01 · FY2021 · CA · contact PI
Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Bind, Placebo-Controlled Phase II to Phase III Study$42,581
R01 · FY2021 · CA · contact PI
Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Bind, Placebo-Controlled Phase II to Phase III Study$195,405
R01 · FY2020 · CA · contact PI
Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Bind, Placebo-Controlled Phase II to Phase III Study$406,827
R01 · FY2019 · CA · contact PI
Chemotherapy-Induced Peripheral Neuropathy (CIPN) Measurement Validation$77,500
R03 · FY2016 · CA · contact PI
Chemotherapy-Induced Peripheral Neuropathy (CIPN) Measurement Validation$77,563
R03 · FY2015 · CA · contact PI